{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:44:45Z","timestamp":1790649885735,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Patients with coronary-artery disease (CAD) and type 2 diabetes mellitus (T2DM) are often in a hypercoagulable state and have an increased thrombosis risk. We aimed to evaluate the effects of sodium\/glucose cotransporter 2 inhibitors (SGLT2is) on coagulation function and explore their potential role in regulating coagulation in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study between June 2020 and June 2024 in patients with CAD and T2DM. Eligible patients were assigned to either the SGLT2i or non-SGLT2i group. Clinical information, laboratory tests, and echocardiographic (EKG) examination results were retrieved. We performed inter- and intragroup comparisons of coagulation function measurements before and after treatment, and also conducted regression analysis to assess the impact of treatment on coagulation function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 121 patients were included, with 49 and 72 in the SGLT2i and non-SGLT2i groups, respectively. After 30 days of treatment, antithrombin III (AT-III) activity increased by 5.39% (<jats:italic>P<\/jats:italic>\u2009=\u20090.026) in the SGLT2i group, but slightly decreased in the non-SGLT2i group. SGLT2 is also decreased D-dimer levels by 95\u2005mg\/L (group <jats:italic>P<\/jats:italic>\u2009=\u20090.051, group:time <jats:italic>P<\/jats:italic>\u2009=\u20090.075). Further regression analysis showed a significant interaction between group and time for AT-III and D-dimer (<jats:italic>P<\/jats:italic>\u2009=\u20090.026 and <jats:italic>P<\/jats:italic>\u2009=\u20090.039). Additionally, prothrombin time (PT) showed a slight increase after SGLT2i treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SGLT2is could affect coagulation function by prolonging coagulation time and increasing anticoagulatory activity in patients with T2DM and CAD. These drugs could be used to ameliorate hypercoagulable states and reduce thrombosis risk in these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1588797","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:13:26Z","timestamp":1746594806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of sodium\/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"XiaoYue","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoBin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.trsl.2010.02.001","article-title":"Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event","volume":"155","author":"Abdullah","year":"2010","journal-title":"Transl Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2337\/dc19-1902","article-title":"Coronary artery disease and type 2 diabetes: a proteomic study","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1182\/blood.2019000820","article-title":"How I treat unexplained arterial thrombosis","volume":"136","author":"May","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (Sglt1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J Cell Biochem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity Index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1017\/s0007114517002926","article-title":"Involvement of NLRP3 inflammasome in the impacts of sodium and potassium on insulin resistance in normotensive Asians","volume":"119","author":"Wan","year":"2018","journal-title":"Br J Nutr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0128870","DOI":"10.1371\/journal.pone.0128870","article-title":"Elevated sodium and dehydration stimulate inflammatory signaling in endothelial cells and promote atherosclerosis","volume":"10","author":"Dmitrieva","year":"2015","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1339094","DOI":"10.3389\/fcvm.2024.1339094","article-title":"SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study","volume":"11","author":"Shi","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/jcmm.14233","article-title":"Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence","volume":"24","author":"Khemais-Benkhiat","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1042\/cs20210094","article-title":"Angiotensin ii up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice","volume":"135","author":"Miyata","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","article-title":"Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2","volume":"119","author":"Chen","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"30764","DOI":"10.1038\/s41598-024-30764-0","article-title":"Effects of empagliflozin and dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-024-02539-x","article-title":"SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives","volume":"23","author":"Morciano","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"992937","DOI":"10.3389\/fendo.2022.992937","article-title":"Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tem.2024.03.002","article-title":"Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors","volume":"35","author":"Mashayekhi","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12933-024-02495-6","article-title":"The potential anti-arrhythmic effect of SGLT2 inhibitors","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15223","article-title":"SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices","author":"Mariani","year":"2025","journal-title":"ESC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1588797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:13:27Z","timestamp":1746594807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1588797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":23,"alternative-id":["10.3389\/fcvm.2025.1588797"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1588797","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"article-number":"1588797"}}